In Brief: Biomatrix Synvisc
This article was originally published in The Gray Sheet
Executive Summary
Biomatrix Synvisc: FDA's Orthopedic and Rehabilitation Devices Panel will review the injectable biopolymer at a Nov. 20 meeting, the company reports. Used to treat osteoarthritis of the knee, Synvisc currently is marketed in Canada by Rhone-Poulenc Rorer and in Sweden by Roche AB; the product also is approved in the European Economic Area, the company says...